131I Intake and Regulatory Compliance Following Administration of Capsular 131I Sodium Iodide for Treatment of Thyroid Disorders.

Health Phys

Atlantic Medical Group Radiology at Morristown, 100 Madison Avenue, Morristown, NJ 07960.

Published: February 2022

Intake of 131I by nuclear medicine technologists and physician Authorized Users was evaluated using bioassay data from administration of 131I sodium iodide in capsular form during a 5-year period. Maximum estimated annual intake of 131I sodium iodide, based on bioassay measurements performed at 24 hours post administration, ranged from 10.9 to 35.6 kBq for all staff. Intake by Authorized Users was higher than that by nuclear medicine technologists due to state requirement for Authorized Users to physically administer therapeutic dosages of radiopharmaceuticals. All intake values were less than 10% of the 131I thyroid ALI of 50 microcurie3 (1,850 kBq), indicating that monitoring may be discontinued for staff participating in routine administration of 131I capsules in which volatilization is not suspected. Elimination of bioassay performance has permitted more flexibility in patient scheduling and improved workflow and efficiency.

Download full-text PDF

Source
http://dx.doi.org/10.1097/HP.0000000000001509DOI Listing

Publication Analysis

Top Keywords

131i sodium
12
sodium iodide
12
authorized users
12
intake 131i
8
nuclear medicine
8
medicine technologists
8
administration 131i
8
131i
7
131i intake
4
intake regulatory
4

Similar Publications

Redifferentiation Therapies in Thyroid Oncology: Molecular and Clinical Aspects.

J Clin Med

November 2024

Department of Nuclear Medicine, Gruppo Ospedaliero Moncucco, 6900 Lugano, Switzerland.

Since the 1940s, 131-I radioiodine therapy (RIT) has been the primary treatment for metastatic differentiated thyroid cancer (DTC). Approximately half of these patients respond favorably to RIT, achieving partial or complete remission or maintaining long-term stable disease, while the other half develop radioiodine-refractory DTC (RAI-R DTC). The main genomic alteration involved in radioiodine resistance is the activated mitogen-activated protein kinase (MAPK) pathway, which results in the loss of sodium iodide symporters (NIS).

View Article and Find Full Text PDF

Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAF-associated thyroid carcinoma.

Clin Transl Med

May 2024

Department of Thyroid and Neck Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Medical University, Tianjin, China.

Background: BRAF is the most common genetic mutation in differentiated thyroid cancer (DTC) occurring in 60% of patients and drives malignant tumour cell phenotypes including proliferation, metastasis and immune-escape. BRAF-mutated papillary thyroid cancer (PTC) also displays greatly reduced expression of thyroid differentiation markers, thus tendency to radioactive iodine (RAI) refractory and poor prognosis. Therefore, understanding the molecular mechanisms and main oncogenic events underlying BRAF will guide future therapy development.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!